{"id":454507,"date":"2021-03-10T07:03:07","date_gmt":"2021-03-10T12:03:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454507"},"modified":"2021-03-10T07:03:07","modified_gmt":"2021-03-10T12:03:07","slug":"azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/","title":{"rendered":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DELRAY BEACH, Fla., March  10, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fb8WP2auS6oUKlQDT2HLlSra0-swipLoGYlJJ1bwNhz4dsIcgAGr126_SVdX5lAKPnaGhwsibHPDaJW_7EWKEhvL8DtHaB-M7b7KOTdYw2Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">AzurRx BioPharma, Inc.<\/a>\u00a0(\u201cAzurRx\u201d or the \u201cCompany\u201d) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases,\u00a0announced today that James Sapirstein, Chairman and Chief Executive Officer, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Thursday, March 18, 2021. All registered conference attendees will be able to view the prerecorded virtual presentation.<\/p>\n<p align=\"justify\">During the presentation, Mr. Sapirstein will provide an overview of AzurRx\u2019s business and clinical development programs and discuss anticipated 2021 milestones. Additionally, during the conference, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies.<\/p>\n<p align=\"justify\">Details of AzurRx\u2019s presentation are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: bottom\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"max-width:83%;width:83%;min-width:83%;vertical-align: bottom\">2021 Emerging Growth Virtual Conference<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Date:\u00a0<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">Wednesday, March 17 to Thursday, March 18, 2021<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Time:<\/strong><br \/>\n            <br \/>\n            <strong>Registration:<\/strong><br \/>\n            \n          <\/td>\n<td style=\"vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">9:00 a.m. ET to 5:00 p.m. ET<br \/><a href=\"https:\/\/www.m-vest.com\/events\/2021-emerging-growth-virtual-conference\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.m-vest.com\/events\/2021-emerging-growth-virtual-conference<\/a><\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About AzurRx BioPharma, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information visit www.azurrx.com.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead, represent only the Company\u2019s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company\u2019s control. It is possible that the Company\u2019s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial; and the Company\u2019s success in raising additional financing to support its operations. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company\u2019s financial results, including those related to the clinical development of MS1819, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company\u2019s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading \u201cRisk Factors,\u201d as well as the Company\u2019s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.<\/p>\n<p align=\"justify\">\n        <strong>For more information:<\/strong>\n      <\/p>\n<p align=\"justify\">AzurRx BioPharma, Inc.<br \/>1615 South Congress Avenue<br \/>Suite 103<br \/>Delray Beach, Florida 33445<br \/>Phone: (646) 699-7855<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xo0_gvNFVGgBn9TeaRKptASzFjLo9aU4_d4NPaDyWC8Q2plBzrYkB_UleAURu51rd7u4qC7CyoB6p__AT7jNk6-d0fQHahJdh5KjKPnFPaM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mailto:info@azurrx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eIo9r93FELWmbhBag03Ynn34NNr4f1nZgDN4JYlQ0rZ8E09O3Oaleg3CKeUQRq6yqjb6abSvRTkvVB9GL2LVQMGTVp7JIThsYlZW2g0ll8Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Tiberend Strategic Advisors, Inc.<\/a><br \/>\n        <br \/>Johanna Bennett\/Ingrid Mezo<br \/>(212) 375-2665\/(646) 604-5150<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j7Y4oZWsNbudLESS6V_YkBqVJ4ZJuECUNv99WRIx9hCeCTHKNCONMb4RUsE2WP4vTquKo3-gaXv_FQOvbg5S3GNCe5Fvg1MJ0rWvgdmn2BY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jbennett@tiberend.com<\/a>\/<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cFa92RgeZRINkEj7hV6joKs278DwdOcdG72TuB3fHPCqvh5Ff2dkb2LTUgJngdMMi0QoPI5G-qOaa6pNuapv2wUiYjJ1N29sOAv8IoLSAho=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">imezo@tiberend.com<\/a>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/30cad467-8b2f-4903-8bda-21f542fe5d62\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc.\u00a0(\u201cAzurRx\u201d or the \u201cCompany\u201d) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases,\u00a0announced today that James Sapirstein, Chairman and Chief Executive Officer, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Thursday, March 18, 2021. All registered conference attendees will be able to view the prerecorded virtual presentation. During the presentation, Mr. Sapirstein will provide an overview of AzurRx\u2019s business and clinical development programs and discuss anticipated 2021 milestones. Additionally, during the conference, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Details &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454507","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc.\u00a0(\u201cAzurRx\u201d or the \u201cCompany\u201d) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases,\u00a0announced today that James Sapirstein, Chairman and Chief Executive Officer, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Thursday, March 18, 2021. All registered conference attendees will be able to view the prerecorded virtual presentation. During the presentation, Mr. Sapirstein will provide an overview of AzurRx\u2019s business and clinical development programs and discuss anticipated 2021 milestones. Additionally, during the conference, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Details &hellip; Continue reading &quot;AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T12:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)\",\"datePublished\":\"2021-03-10T12:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/\"},\"wordCount\":618,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/\",\"name\":\"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\",\"datePublished\":\"2021-03-10T12:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/","og_locale":"en_US","og_type":"article","og_title":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk","og_description":"DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) &#8212; AzurRx BioPharma, Inc.\u00a0(\u201cAzurRx\u201d or the \u201cCompany\u201d) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant\u00a0therapies for\u00a0gastrointestinal (GI) diseases,\u00a0announced today that James Sapirstein, Chairman and Chief Executive Officer, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Thursday, March 18, 2021. All registered conference attendees will be able to view the prerecorded virtual presentation. During the presentation, Mr. Sapirstein will provide an overview of AzurRx\u2019s business and clinical development programs and discuss anticipated 2021 milestones. Additionally, during the conference, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Details &hellip; Continue reading \"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T12:03:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)","datePublished":"2021-03-10T12:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/"},"wordCount":618,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/","name":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=","datePublished":"2021-03-10T12:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgxMCM0MDQ3MjQ4IzIwODIyMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azurrx-biopharma-to-present-at-the-maxim-group-emerging-growth-virtual-conference-march-17-18\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454507"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454507\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}